Deliverthera
1 known investors
Ponce Aurora (deliverthera.com) develops small molecule kinase inhibitors discovered through DNA-encoded library (DEL) screening, including a multi-kinase inhibitor targeting ABL1-T315I and other tyrosine kinases for patients with Ph+ acute lymphocytic leukemia. The company also develops selective JAK/TYK2 inhibitors as senomorphic therapies to regulate the senescence-associated secretory phenotype (SASP) in aging and age-related diseases.
BiotechDeep TechLongevity